Nurix Therapeutics (NRIX) investor relations material

Executive summary

• Focused on developing targeted protein degradation medicines for cancer, inflammatory, and autoimmune diseases, leveraging an AI-integrated discovery engine and proprietary DEL-AI platform.

• Lead clinical programs include bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607, all in early or pivotal clinical development stages.

• Advanced registrational program for bexobrutideg in relapsed/refractory CLL, with Phase 2 and planned Phase 3 trials underway.

• Collaborations with Gilead, Sanofi, and Pfizer have generated $487M in non-dilutive financing and eligibility for up to $6.1B in future milestone payments.

• Maintains strong liquidity position with $540.7M in cash, cash equivalents, and marketable securities as of February 28, 2026.

Financial highlights

• Collaboration revenue for the quarter was $6.3M, down from $18.5M year-over-year, mainly due to the conclusion of the initial research term with Sanofi.

• Net loss for the quarter was $87.2M ($0.79 per share), compared to $56.4M ($0.67 per share) in the prior year period.

• Research and development expenses increased to $84.1M from $69.7M year-over-year, driven by higher clinical and personnel costs.

• General and administrative expenses rose to $14.6M from $11.7M year-over-year.

• Cash, cash equivalents, and marketable securities decreased to $540.7M from $592.9M sequentially.

Outlook and guidance

• Current cash position is expected to fund operations for at least the next 12 months; substantial additional funding will be needed for long-term plans and commercialization.

• Anticipates continued operating losses and negative cash flows until significant product sales are achieved.

• Anticipates IND submission for bexobrutideg in inflammatory and autoimmune indications in 2026.

• Expects substantial research collaboration milestones from partnerships with Gilead, Sanofi, and Pfizer.

• Plans to initiate global Phase 3 trial for bexobrutideg by mid-2026.